Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies
Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to...
Saved in:
Published in | Vaccine Vol. 25; no. 29; pp. 5308 - 5314 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Elsevier Ltd
20.07.2007
Elsevier Elsevier Limited |
Subjects | |
Online Access | Get full text |
ISSN | 0264-410X 1873-2518 |
DOI | 10.1016/j.vaccine.2007.05.021 |
Cover
Abstract | Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to polysaccharide meningococcal vaccine. Twenty-four antibody deficient children of mean age 11.2±3.5 years, and 15 sex and age-matched healthy volunteers were enrolled. All subjects received meningococcal polysaccharide vaccine A+C; blood samples were collected before vaccination and 3 weeks after vaccination. Following vaccination, the serum bactericidal antibody (SBA) geometric mean titre was significantly increased compared to the prevaccination level in the patient group (8.98 versus 1.63, P<0.001) and the control group (12.13 versus 1.26, P<0.001). All controls had a protective SBA response (SBA titre of ≥8 post-vaccination or rise of ≥4-fold from pre- to post-vaccination), whereas only 16 of 24 patients (66.6%) had a protective response (P=0.014). The non-responder patients included 5 cases with common variable immunodeficiency, two cases with hyper IgM syndrome, and one case with IgG subclass deficiency. This study indicates that some patients with primary antibody deficiencies can produce protective post-vaccination titres similar to the normal population, despite the common perception that patients with primary antibody deficiencies respond poorly to vaccination. This supports the use of polysaccharide-containing vaccines in these patients. |
---|---|
AbstractList | Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to polysaccharide meningococcal vaccine. Twenty-four antibody deficient children of mean age 11.2±3.5 years, and 15 sex and age-matched healthy volunteers were enrolled. All subjects received meningococcal polysaccharide vaccine A+C; blood samples were collected before vaccination and 3 weeks after vaccination. Following vaccination, the serum bactericidal antibody (SBA) geometric mean titre was significantly increased compared to the prevaccination level in the patient group (8.98versus1.63,P<0.001) and the control group (12.13versus1.26,P<0.001). All controls had a protective SBA response (SBA titre of >=8 post-vaccination or rise of >=4-fold from pre- to post-vaccination), whereas only 16 of 24 patients (66.6%) had a protective response (P=0.014). The non-responder patients included 5 cases with common variable immunodeficiency, two cases with hyper IgM syndrome, and one case with IgG subclass deficiency. This study indicates that some patients with primary antibody deficiencies can produce protective post-vaccination titres similar to the normal population, despite the common perception that patients with primary antibody deficiencies respond poorly to vaccination. This supports the use of polysaccharide-containing vaccines in these patients. Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to polysaccharide meningococcal vaccine. Twenty-four antibody deficient children of mean age 11.2+/-3.5 years, and 15 sex and age-matched healthy volunteers were enrolled. All subjects received meningococcal polysaccharide vaccine A+C; blood samples were collected before vaccination and 3 weeks after vaccination. Following vaccination, the serum bactericidal antibody (SBA) geometric mean titre was significantly increased compared to the prevaccination level in the patient group (8.98 versus 1.63, P<0.001) and the control group (12.13 versus 1.26, P<0.001). All controls had a protective SBA response (SBA titre of >or=8 post-vaccination or rise of >or=4-fold from pre- to post-vaccination), whereas only 16 of 24 patients (66.6%) had a protective response (P=0.014). The non-responder patients included 5 cases with common variable immunodeficiency, two cases with hyper IgM syndrome, and one case with IgG subclass deficiency. This study indicates that some patients with primary antibody deficiencies can produce protective post-vaccination titres similar to the normal population, despite the common perception that patients with primary antibody deficiencies respond poorly to vaccination. This supports the use of polysaccharide-containing vaccines in these patients.Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to polysaccharide meningococcal vaccine. Twenty-four antibody deficient children of mean age 11.2+/-3.5 years, and 15 sex and age-matched healthy volunteers were enrolled. All subjects received meningococcal polysaccharide vaccine A+C; blood samples were collected before vaccination and 3 weeks after vaccination. Following vaccination, the serum bactericidal antibody (SBA) geometric mean titre was significantly increased compared to the prevaccination level in the patient group (8.98 versus 1.63, P<0.001) and the control group (12.13 versus 1.26, P<0.001). All controls had a protective SBA response (SBA titre of >or=8 post-vaccination or rise of >or=4-fold from pre- to post-vaccination), whereas only 16 of 24 patients (66.6%) had a protective response (P=0.014). The non-responder patients included 5 cases with common variable immunodeficiency, two cases with hyper IgM syndrome, and one case with IgG subclass deficiency. This study indicates that some patients with primary antibody deficiencies can produce protective post-vaccination titres similar to the normal population, despite the common perception that patients with primary antibody deficiencies respond poorly to vaccination. This supports the use of polysaccharide-containing vaccines in these patients. Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to polysaccharide meningococcal vaccine. Twenty-four antibody deficient children of mean age 11.2+/-3.5 years, and 15 sex and age-matched healthy volunteers were enrolled. All subjects received meningococcal polysaccharide vaccine A+C; blood samples were collected before vaccination and 3 weeks after vaccination. Following vaccination, the serum bactericidal antibody (SBA) geometric mean titre was significantly increased compared to the prevaccination level in the patient group (8.98 versus 1.63, P<0.001) and the control group (12.13 versus 1.26, P<0.001). All controls had a protective SBA response (SBA titre of >or=8 post-vaccination or rise of >or=4-fold from pre- to post-vaccination), whereas only 16 of 24 patients (66.6%) had a protective response (P=0.014). The non-responder patients included 5 cases with common variable immunodeficiency, two cases with hyper IgM syndrome, and one case with IgG subclass deficiency. This study indicates that some patients with primary antibody deficiencies can produce protective post-vaccination titres similar to the normal population, despite the common perception that patients with primary antibody deficiencies respond poorly to vaccination. This supports the use of polysaccharide-containing vaccines in these patients. Abstract Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to polysaccharide meningococcal vaccine. Twenty-four antibody deficient children of mean age 11.2 ± 3.5 years, and 15 sex and age-matched healthy volunteers were enrolled. All subjects received meningococcal polysaccharide vaccine A + C; blood samples were collected before vaccination and 3 weeks after vaccination. Following vaccination, the serum bactericidal antibody (SBA) geometric mean titre was significantly increased compared to the prevaccination level in the patient group (8.98 versus 1.63, P < 0.001) and the control group (12.13 versus 1.26, P < 0.001). All controls had a protective SBA response (SBA titre of ≥8 post-vaccination or rise of ≥4-fold from pre- to post-vaccination), whereas only 16 of 24 patients (66.6%) had a protective response ( P = 0.014). The non-responder patients included 5 cases with common variable immunodeficiency, two cases with hyper IgM syndrome, and one case with IgG subclass deficiency. This study indicates that some patients with primary antibody deficiencies can produce protective post-vaccination titres similar to the normal population, despite the common perception that patients with primary antibody deficiencies respond poorly to vaccination. This supports the use of polysaccharide-containing vaccines in these patients. Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to polysaccharide meningococcal vaccine. Twenty-four antibody deficient children of mean age 11.2±3.5 years, and 15 sex and age-matched healthy volunteers were enrolled. All subjects received meningococcal polysaccharide vaccine A+C; blood samples were collected before vaccination and 3 weeks after vaccination. Following vaccination, the serum bactericidal antibody (SBA) geometric mean titre was significantly increased compared to the prevaccination level in the patient group (8.98 versus 1.63, P<0.001) and the control group (12.13 versus 1.26, P<0.001). All controls had a protective SBA response (SBA titre of ≥8 post-vaccination or rise of ≥4-fold from pre- to post-vaccination), whereas only 16 of 24 patients (66.6%) had a protective response (P=0.014). The non-responder patients included 5 cases with common variable immunodeficiency, two cases with hyper IgM syndrome, and one case with IgG subclass deficiency. This study indicates that some patients with primary antibody deficiencies can produce protective post-vaccination titres similar to the normal population, despite the common perception that patients with primary antibody deficiencies respond poorly to vaccination. This supports the use of polysaccharide-containing vaccines in these patients. Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various microorganisms including encapsulated bacteria. This study was performed in order to evaluate bactericidal antibody response of these patients to polysaccharide meningococcal vaccine. Twenty-four antibody deficient children of mean age 11.2±3.5 years, and 15 sex and age-matched healthy volunteers were enrolled. All subjects received meningococcal polysaccharide vaccine A+C; blood samples were collected before vaccination and 3 weeks after vaccination. Following vaccination, the serum bactericidal antibody (SBA) geometric mean titre was significantly increased compared to the prevaccination level in the patient group (8.98 versus 1.63, P<0.001) and the control group (12.13 versus 1.26, P<0.001). All controls had a protective SBA response (SBA titre of >=8 post-vaccination or rise of >=4-fold from pre- to post-vaccination), whereas only 16 of 24 patients (66.6%) had a protective response (P=0.014). The non-responder patients included 5 cases with common variable immunodeficiency, two cases with hyper IgM syndrome, and one case with IgG subclass deficiency. This study indicates that some patients with primary antibody deficiencies can produce protective post-vaccination titres similar to the normal population, despite the common perception that patients with primary antibody deficiencies respond poorly to vaccination. This supports the use of polysaccharide-containing vaccines in these patients. |
Author | Rezaei, Nima Ahmadi, Hojat Nejati, Mehdi Aghamohammadi, Asghar Moin, Mostafa Kamali, Samineh Tabaraei, Bahman Read, Robert C. Siadat, Seyed Davar Pourpak, Zahra Norouzian, Dariush |
Author_xml | – sequence: 1 givenname: Nima surname: Rezaei fullname: Rezaei, Nima email: rezaei_nima@hbi.ir, nima_rezaei@farabi.tums.ac.ir organization: Department of Allergy and Clinical Immunology of Children Medical Center, Immunology, Asthma and Allergy Research Institute, Medical Sciences/University of Tehran, Tehran, Iran – sequence: 2 givenname: Asghar surname: Aghamohammadi fullname: Aghamohammadi, Asghar organization: Department of Allergy and Clinical Immunology of Children Medical Center, Immunology, Asthma and Allergy Research Institute, Medical Sciences/University of Tehran, Tehran, Iran – sequence: 3 givenname: Seyed Davar surname: Siadat fullname: Siadat, Seyed Davar organization: Department of Bacterial Vaccine and Antigen Production, Pasteur Institute of Iran, Tehran, Iran – sequence: 4 givenname: Mehdi surname: Nejati fullname: Nejati, Mehdi organization: Department of Bacterial Vaccine and Antigen Production, Pasteur Institute of Iran, Tehran, Iran – sequence: 5 givenname: Hojat surname: Ahmadi fullname: Ahmadi, Hojat organization: Department of Bacterial Vaccine and Antigen Production, Pasteur Institute of Iran, Tehran, Iran – sequence: 6 givenname: Mostafa surname: Moin fullname: Moin, Mostafa organization: Department of Allergy and Clinical Immunology of Children Medical Center, Immunology, Asthma and Allergy Research Institute, Medical Sciences/University of Tehran, Tehran, Iran – sequence: 7 givenname: Zahra surname: Pourpak fullname: Pourpak, Zahra organization: Department of Allergy and Clinical Immunology of Children Medical Center, Immunology, Asthma and Allergy Research Institute, Medical Sciences/University of Tehran, Tehran, Iran – sequence: 8 givenname: Samineh surname: Kamali fullname: Kamali, Samineh organization: Department of Allergy and Clinical Immunology of Children Medical Center, Immunology, Asthma and Allergy Research Institute, Medical Sciences/University of Tehran, Tehran, Iran – sequence: 9 givenname: Dariush surname: Norouzian fullname: Norouzian, Dariush organization: Department of Bacterial Vaccine and Antigen Production, Pasteur Institute of Iran, Tehran, Iran – sequence: 10 givenname: Bahman surname: Tabaraei fullname: Tabaraei, Bahman organization: Department of Bacterial Vaccine and Antigen Production, Pasteur Institute of Iran, Tehran, Iran – sequence: 11 givenname: Robert C. surname: Read fullname: Read, Robert C. organization: Section of Infection, Inflammation and Immunity, School of Medicine and Biomedical Sciences, The University of Sheffield, Sheffield, United Kingdom |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18887029$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17574314$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkt-KEzEUxoOsuN3qIygB0bvWk8lkJoOoSPEfLHixCt6FNDmzTZ0m3WS60mfwpc20lUJBKkyYm9_5zjnf-a7IhQ8eCXnKYMqAVa-W03ttjPM4LQDqKYgpFOwBGTFZ80khmLwgIyiqclIy-HFJrlJaAoDgrHlELlkt6pKzckR-32DcrOhcmx6jM87qjmrfu3mwWxoxrYNPSPtAE8ZwG8NmTWd0Hbptyt0XOjqLdIXe-dtggjG5ej-W7l3w1HlqFq6zET395foFXUe30nF7bGGxzV3R55cek4et7hI-OfzH5PvHD99mnyfXXz99mb2_nhhRsX5SNQiSN7KxvBW6YGYupACONXJssJFFO29KVlmO2HAOJUMjuRUIrBQW6paPycu97jqGuw2mXq1cMth12mPYJFVDVfE6G3QOLIAXbPjG5PkJuAyb6PMSignRgJQVazL17EBt5iu06mCG-nuNDLw4ADplK9uosy_pyEkpaygGIbHnTAwpRWyPCKghHWqpDulQQzoUCAW7MV-f1BnX7y7VR-26s9Xv9tWYb3PvMKq0uxxaF9H0ygZ3VuHtiYLpnHd51Z-4xXT0TKVCgboZ8jvEF-qcXCmHxd_8W-A_BvgDowgEOg |
CODEN | VACCDE |
CitedBy_id | crossref_primary_10_1016_j_humimm_2010_01_019 crossref_primary_10_1111_j_1365_2249_2008_03790_x crossref_primary_10_1111_j_1749_6632_2011_06239_x crossref_primary_10_1111_trf_13869 crossref_primary_10_25100_cm_v53i2_4832 crossref_primary_10_1007_s10875_007_9135_6 crossref_primary_10_1128_CVI_00489_07 crossref_primary_10_4014_jmb_2401_01018 crossref_primary_10_5812_jjm_5007 crossref_primary_10_1016_j_vaccine_2011_12_076 crossref_primary_10_1016_j_jaci_2012_07_002 crossref_primary_10_1586_1744666X_2014_880654 crossref_primary_10_1111_j_1365_3083_2011_02561_x crossref_primary_10_1016_S1684_1182_10_60002_3 crossref_primary_10_1016_S1665_2681_19_31765_X crossref_primary_10_1007_s10238_009_0049_x crossref_primary_10_1128_CVI_00389_09 crossref_primary_10_1007_s10875_022_01317_2 crossref_primary_10_1007_BF03179226 |
Cites_doi | 10.1007/s10875-006-9047-x 10.1111/j.1574-695X.2000.tb01460.x 10.1097/01.all.0000191888.97397.b3 10.1016/j.jaci.2005.12.1347 10.1016/j.jaci.2005.09.051 10.1016/S0952-7915(00)00098-4 10.1081/IMM-120027687 10.1056/NEJMsb035678 10.1023/A:1020660416865 10.1006/clim.1999.4725 10.1016/j.vaccine.2003.08.040 10.1159/000095469 10.1016/0264-410X(92)90091-W 10.1542/peds.9.6.722 10.1016/j.vaccine.2005.01.051 10.1016/S0264-410X(00)00333-9 10.1016/j.vaccine.2006.03.034 10.1016/j.jaci.2004.10.048 10.1128/CDLI.12.7.825-832.2005 10.1001/jama.279.6.435 10.1084/jem.129.6.1307 10.4049/jimmunol.130.6.2882 10.1128/CDLI.10.5.780-786.2003 10.1128/CDLI.4.2.156-167.1997 10.1097/00006454-198909000-00013 10.1056/NEJM199508173330707 10.1542/peds.60.5.673 10.1046/j.1365-2249.2000.01131.x 10.1542/peds.2004-2514 |
ContentType | Journal Article |
Copyright | 2007 Elsevier Ltd Elsevier Ltd 2007 INIST-CNRS Copyright Elsevier Limited Jul 20, 2007 |
Copyright_xml | – notice: 2007 Elsevier Ltd – notice: Elsevier Ltd – notice: 2007 INIST-CNRS – notice: Copyright Elsevier Limited Jul 20, 2007 |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7T7 8FD FR3 P64 7X8 |
DOI | 10.1016/j.vaccine.2007.05.021 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database PML(ProQuest Medical Library) Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) ProQuest Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) Technology Research Database Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | Research Library Prep MEDLINE - Academic MEDLINE Technology Research Database |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-2518 |
EndPage | 5314 |
ExternalDocumentID | 3420797121 17574314 18887029 10_1016_j_vaccine_2007_05_021 S0264410X07005889 1_s2_0_S0264410X07005889 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADFRT ADMUD ADNMO AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GNUQQ GUQSH HCIFZ HMCUK HZ~ IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 GBLVA HEJ HLV HMG HMK HMO HVGLF HX~ P-8 R2- RIG SAE SEW SIN SVS WOW WUQ XPP ZGI ZXP AAIAV ABLVK ABYKQ AESVU AJBFU EFLBG LCYCR QYZTP AAYWO AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP AIGII APXCP CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7T7 8FD FR3 P64 7X8 |
ID | FETCH-LOGICAL-c561t-69e083989d3f5a21cb58503e7e3e9e982fb9416d3ee933041ec83d5e0145d07f3 |
IEDL.DBID | .~1 |
ISSN | 0264-410X |
IngestDate | Thu Sep 04 17:26:32 EDT 2025 Fri Sep 05 10:42:22 EDT 2025 Wed Aug 13 05:08:57 EDT 2025 Wed Feb 19 02:12:30 EST 2025 Mon Jul 21 09:15:33 EDT 2025 Tue Jul 01 03:45:00 EDT 2025 Thu Apr 24 23:04:47 EDT 2025 Fri Feb 23 02:32:31 EST 2024 Sun Feb 23 10:19:18 EST 2025 Tue Aug 26 16:34:26 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 29 |
Keywords | Polysaccharide vaccine Primary antibody deficiencies Serum bactericidal antibody assay Antibody response Meningococcal disease Human Immune response Antibody Vaccination Neisseriaceae Neisseria meningitidis Vaccine Infection Bacteriosis Bacteria Micrococcales Serum Child Polysaccharide Humoral immunity |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c561t-69e083989d3f5a21cb58503e7e3e9e982fb9416d3ee933041ec83d5e0145d07f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 17574314 |
PQID | 1559088619 |
PQPubID | 105530 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_70663774 proquest_miscellaneous_20321321 proquest_journals_1559088619 pubmed_primary_17574314 pascalfrancis_primary_18887029 crossref_primary_10_1016_j_vaccine_2007_05_021 crossref_citationtrail_10_1016_j_vaccine_2007_05_021 elsevier_sciencedirect_doi_10_1016_j_vaccine_2007_05_021 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X07005889 elsevier_clinicalkey_doi_10_1016_j_vaccine_2007_05_021 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2007-07-20 |
PublicationDateYYYYMMDD | 2007-07-20 |
PublicationDate_xml | – month: 07 year: 2007 text: 2007-07-20 day: 20 |
PublicationDecade | 2000 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford – name: Netherlands – name: Kidlington |
PublicationTitle | Vaccine |
PublicationTitleAlternate | Vaccine |
PublicationYear | 2007 |
Publisher | Elsevier Ltd Elsevier Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
References | Goldacker, Warnatz (bib40) 2005; 5 Notarangelo, Casanova, Conley, Chapel, Fischer, Puck (bib7) 2006; 117 WHO (bib25) 1999 Goldschneider, Gotschlich, Artenstein (bib36) 1969; 129 Offit, Peter (bib13) 2003; 349 Aghamohammadi, Fiorini, Moin, Parvaneh, Teimourian, Yeganeh (bib24) 2006; 141 Shepard, Ortega-Sanchez, Scott, Rosenstein (bib33) 2005; 115 Kline (bib28) 1989; 8 Lepow, Goldschneider, Gold, Randolph, Gotschlich (bib35) 1977; 60 Hermaszewski, Webster (bib8) 1993; 86 Casali, Schettino (bib22) 1996; 210 Pollard, Frasch (bib29) 2001; 19 Borrow, Balmer, Miller (bib32) 2005; 23 Rosenstein, Levine, Taylor, Evans, Plikaytis, Wenger (bib20) 1998; 279 Girard, Preziosi, Aguado, Kieny (bib14) 2006; 24 Jodar, Griffiths, Feavers (bib38) 2004; 22 Bonilla, Geha (bib6) 2006; 117 Maslanka, Gheesling, Libutti, Donaldson, Harakeh, Dykes (bib26) 1997; 4 Pahari, Pal, Lyall (bib17) 2004; 41 Cunningham-Rundles, Bodian (bib9) 1999; 92 Zimmerman (bib11) 2005; 72 Griffiss, Goroff (bib37) 1983; 130 WHO. Requirements for meningococcal polysaccharide vaccine. World Health Organization technical report series, no. 594. Geneva, Switzerland: World Health Organization; 1976. Carsetti, Rosado, Donnanno, Guazzi, Soresina, Meini (bib43) 2005; 115 Moin, Aghamohammadi, Farhoudi, Pourpak, Rezaei, Movahedi (bib27) 2004; 33 Aghamohammadi, Farhoudi, Moin, Rezaei, Kouhi, Pourpak (bib16) 2005; 12 Stiehm, Ochs, Winkelstein (bib3) 2004 Farhoudi, Aghamohammadi, Moin, Rezaei, Pourpak, Movahedi (bib23) 2005; 15 Bell (bib18) 1992; 39 Aghamohammadi, Moein, Farhoudi, Pourpak, Rezaei, Abolmaali (bib2) 2002; 22 Granoff, Feavers, Borrow (bib15) 2004 Bilukha, Rosenstein (bib12) 2005; 54 Borrow, Richmond, Kaczmarski, Iverson, Martin, Findlow (bib30) 2000; 28 Bruton (bib5) 1952; 9 Hammarstrom, Vorechovsky, Webster (bib41) 2000; 120 Costantino, Viti, Podda, Velmonte, Nencioni, Rappuoli (bib31) 1992; 10 Aghamohammadi, Moin, Farhoudi, Pourpak, Rezaei, Abolmaali (bib42) 2000; 1 Rezaei, Aghamohammadi, Moin, Pourpak, Movahedi, Gharagozlou (bib1) 2006; 26 Andrews, Borrow, Miller (bib39) 2003; 10 Rosen, Cooper, Wedgwood (bib4) 1995; 333 Kimmel (bib10) 2005; 72 Castgliuolo, Nisini, Quinti, Fattorossi, D’Amelio (bib19) 1986; 57 Hayakawa, Hardy (bib21) 2000; 12 Casali (10.1016/j.vaccine.2007.05.021_bib22) 1996; 210 WHO (10.1016/j.vaccine.2007.05.021_bib25) 1999 Borrow (10.1016/j.vaccine.2007.05.021_bib32) 2005; 23 Zimmerman (10.1016/j.vaccine.2007.05.021_bib11) 2005; 72 Rosenstein (10.1016/j.vaccine.2007.05.021_bib20) 1998; 279 Moin (10.1016/j.vaccine.2007.05.021_bib27) 2004; 33 Hermaszewski (10.1016/j.vaccine.2007.05.021_bib8) 1993; 86 Hayakawa (10.1016/j.vaccine.2007.05.021_bib21) 2000; 12 Shepard (10.1016/j.vaccine.2007.05.021_bib33) 2005; 115 Aghamohammadi (10.1016/j.vaccine.2007.05.021_bib16) 2005; 12 Bell (10.1016/j.vaccine.2007.05.021_bib18) 1992; 39 Aghamohammadi (10.1016/j.vaccine.2007.05.021_bib24) 2006; 141 Costantino (10.1016/j.vaccine.2007.05.021_bib31) 1992; 10 Bruton (10.1016/j.vaccine.2007.05.021_bib5) 1952; 9 Pollard (10.1016/j.vaccine.2007.05.021_bib29) 2001; 19 Borrow (10.1016/j.vaccine.2007.05.021_bib30) 2000; 28 Aghamohammadi (10.1016/j.vaccine.2007.05.021_bib42) 2000; 1 Goldschneider (10.1016/j.vaccine.2007.05.021_bib36) 1969; 129 Rezaei (10.1016/j.vaccine.2007.05.021_bib1) 2006; 26 Andrews (10.1016/j.vaccine.2007.05.021_bib39) 2003; 10 Carsetti (10.1016/j.vaccine.2007.05.021_bib43) 2005; 115 Castgliuolo (10.1016/j.vaccine.2007.05.021_bib19) 1986; 57 Kline (10.1016/j.vaccine.2007.05.021_bib28) 1989; 8 Girard (10.1016/j.vaccine.2007.05.021_bib14) 2006; 24 Pahari (10.1016/j.vaccine.2007.05.021_bib17) 2004; 41 Farhoudi (10.1016/j.vaccine.2007.05.021_bib23) 2005; 15 Maslanka (10.1016/j.vaccine.2007.05.021_bib26) 1997; 4 Stiehm (10.1016/j.vaccine.2007.05.021_bib3) 2004 Rosen (10.1016/j.vaccine.2007.05.021_bib4) 1995; 333 Lepow (10.1016/j.vaccine.2007.05.021_bib35) 1977; 60 10.1016/j.vaccine.2007.05.021_bib34 Hammarstrom (10.1016/j.vaccine.2007.05.021_bib41) 2000; 120 Jodar (10.1016/j.vaccine.2007.05.021_bib38) 2004; 22 Cunningham-Rundles (10.1016/j.vaccine.2007.05.021_bib9) 1999; 92 Bilukha (10.1016/j.vaccine.2007.05.021_bib12) 2005; 54 Kimmel (10.1016/j.vaccine.2007.05.021_bib10) 2005; 72 Goldacker (10.1016/j.vaccine.2007.05.021_bib40) 2005; 5 Griffiss (10.1016/j.vaccine.2007.05.021_bib37) 1983; 130 Offit (10.1016/j.vaccine.2007.05.021_bib13) 2003; 349 Aghamohammadi (10.1016/j.vaccine.2007.05.021_bib2) 2002; 22 Bonilla (10.1016/j.vaccine.2007.05.021_bib6) 2006; 117 Notarangelo (10.1016/j.vaccine.2007.05.021_bib7) 2006; 117 Granoff (10.1016/j.vaccine.2007.05.021_bib15) 2004 |
References_xml | – volume: 22 start-page: 1047 year: 2004 end-page: 1053 ident: bib38 article-title: Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines publication-title: Vaccine – volume: 15 start-page: 177 year: 2005 end-page: 182 ident: bib23 article-title: Distribution of primary immunodeficiency disorders diagnosed in the Children's Medical Center in Iran publication-title: J Investig Allergol Clin Immunol – volume: 41 start-page: 1152 year: 2004 end-page: 1154 ident: bib17 article-title: Recurrent meningitis in association with common variable immune deficiency publication-title: Indian Pediatr – volume: 54 start-page: 1 year: 2005 end-page: 21 ident: bib12 article-title: Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP) publication-title: MMWR Recomm Rep – volume: 23 start-page: 2222 year: 2005 end-page: 2227 ident: bib32 article-title: Meningococcal surrogates of protection–serum bactericidal antibody activity publication-title: Vaccine – year: 1999 ident: bib25 article-title: Standardization and validation of serological assays for the evaluation of immune responses to – volume: 333 start-page: 431 year: 1995 end-page: 440 ident: bib4 article-title: The primary immunodeficiencies publication-title: N Engl J Med – volume: 10 start-page: 691 year: 1992 end-page: 698 ident: bib31 article-title: Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C publication-title: Vaccine – volume: 12 start-page: 825 year: 2005 end-page: 832 ident: bib16 article-title: Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency publication-title: Clin Diagn Lab Immunol – volume: 57 start-page: 68 year: 1986 end-page: 70 ident: bib19 article-title: Immunoglobulin deficiencies and meningococcal disease publication-title: Ann Allergy – volume: 9 start-page: 722 year: 1952 end-page: 728 ident: bib5 article-title: Agammaglobulinemia publication-title: Pediatrics – volume: 349 start-page: 2353 year: 2003 end-page: 2356 ident: bib13 article-title: The meningococcal vaccine—public policy and individual choices publication-title: N Engl J Med – volume: 33 start-page: 81 year: 2004 end-page: 93 ident: bib27 article-title: X-linked agammaglobulinemia: a survey of 33 Iranian patients publication-title: Immunol Invest – volume: 115 start-page: 412 year: 2005 end-page: 417 ident: bib43 article-title: The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency publication-title: J Allergy Clin Immunol – volume: 72 start-page: 1978 year: 2005 end-page: 1980 ident: bib11 article-title: Time of hope for the eventual elimination of meningococcal strains A, C, Y, and W-135 in the United States publication-title: Am Fam Physician – reference: WHO. Requirements for meningococcal polysaccharide vaccine. World Health Organization technical report series, no. 594. Geneva, Switzerland: World Health Organization; 1976. – volume: 129 start-page: 1307 year: 1969 end-page: 1326 ident: bib36 article-title: Human immunity to the meningococcus. I: The role of humoral antibodies publication-title: J Exp Med – volume: 279 start-page: 435 year: 1998 end-page: 439 ident: bib20 article-title: Efficacy of meningococcal vaccine and barriers to vaccination publication-title: JAMA – volume: 12 start-page: 346 year: 2000 end-page: 353 ident: bib21 article-title: Development and function of B-1 cells publication-title: Curr Opin Immunol – volume: 115 start-page: 1220 year: 2005 end-page: 1232 ident: bib33 article-title: Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States publication-title: Pediatrics – volume: 5 start-page: 504 year: 2005 end-page: 509 ident: bib40 article-title: Tackling the heterogeneity of CVID publication-title: Curr Opin Allergy Clin Immunol – volume: 72 start-page: 2049 year: 2005 end-page: 2056 ident: bib10 article-title: Prevention of meningococcal disease publication-title: Am Fam Physician – volume: 86 start-page: 31 year: 1993 end-page: 42 ident: bib8 article-title: Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications publication-title: Q J Med – volume: 130 start-page: 2882 year: 1983 end-page: 2885 ident: bib37 article-title: IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms publication-title: J Immunol – volume: 210 start-page: 167 year: 1996 end-page: 179 ident: bib22 article-title: Structure and function of natural antibodies publication-title: Curr Top Microbiol Immunol – volume: 4 start-page: 156 year: 1997 end-page: 167 ident: bib26 article-title: Standardization and a multilaboratory comparison of publication-title: Clin Diagn Lab Immunol – volume: 39 start-page: 651 year: 1992 end-page: 668 ident: bib18 article-title: Recurrent meningitis in children publication-title: Pediatr Neurol – volume: 141 start-page: 408 year: 2006 end-page: 414 ident: bib24 article-title: Clinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia publication-title: Int Arch Allergy Immunol – volume: 1 start-page: 135 year: 2000 end-page: 140 ident: bib42 article-title: The clinical spectrum of respiratory disease in patients with primary antibody deficiency publication-title: Iran J Allergy Asthma Immunol – volume: 120 start-page: 225 year: 2000 end-page: 231 ident: bib41 article-title: Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID) publication-title: Clin Exp Immunol – volume: 26 start-page: 519 year: 2006 end-page: 532 ident: bib1 article-title: Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian primary immunodeficiency registry publication-title: J Clin Immunol – start-page: 959 year: 2004 end-page: 987 ident: bib15 article-title: Meningococcal vaccines publication-title: Vaccines – volume: 10 start-page: 780 year: 2003 end-page: 786 ident: bib39 article-title: Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England publication-title: Clin Diagn Lab Immunol – volume: 22 start-page: 375 year: 2002 end-page: 380 ident: bib2 article-title: Primary immunodeficiency in Iran: first report of the national registry of PID in children and adults publication-title: J Clin Immunol – volume: 28 start-page: 79 year: 2000 end-page: 85 ident: bib30 article-title: Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine publication-title: FEMS Immunol Med Microbiol – volume: 8 start-page: 630 year: 1989 end-page: 634 ident: bib28 article-title: Review of recurrent bacterial meningitis publication-title: Pediatr Infect Dis J – volume: 117 start-page: 883 year: 2006 end-page: 896 ident: bib7 article-title: Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest publication-title: J Allergy Clin Immunol – start-page: 289 year: 2004 end-page: 355 ident: bib3 article-title: Immunologic disorders: general considerations publication-title: Immunodeficiency disorders in infants and children – volume: 117 start-page: S435 year: 2006 end-page: S441 ident: bib6 article-title: Update on primary immunodeficiency diseases publication-title: J Allergy Clin Immunol – volume: 60 start-page: 673 year: 1977 end-page: 680 ident: bib35 article-title: Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines publication-title: Pediatrics – volume: 92 start-page: 34 year: 1999 end-page: 48 ident: bib9 article-title: Common variable immunodeficiency: clinical and immunological features of 248 patients publication-title: Clin Immunol – volume: 24 start-page: 4692 year: 2006 end-page: 4700 ident: bib14 article-title: A review of vaccine research and development: meningococcal disease publication-title: Vaccine – volume: 19 start-page: 1327 year: 2001 end-page: 1346 ident: bib29 article-title: Development of natural immunity to publication-title: Vaccine – volume: 26 start-page: 519 issue: 6 year: 2006 ident: 10.1016/j.vaccine.2007.05.021_bib1 article-title: Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian primary immunodeficiency registry publication-title: J Clin Immunol doi: 10.1007/s10875-006-9047-x – volume: 1 start-page: 135 issue: 3 year: 2000 ident: 10.1016/j.vaccine.2007.05.021_bib42 article-title: The clinical spectrum of respiratory disease in patients with primary antibody deficiency publication-title: Iran J Allergy Asthma Immunol – volume: 210 start-page: 167 year: 1996 ident: 10.1016/j.vaccine.2007.05.021_bib22 article-title: Structure and function of natural antibodies publication-title: Curr Top Microbiol Immunol – volume: 28 start-page: 79 issue: 1 year: 2000 ident: 10.1016/j.vaccine.2007.05.021_bib30 article-title: Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine publication-title: FEMS Immunol Med Microbiol doi: 10.1111/j.1574-695X.2000.tb01460.x – start-page: 959 year: 2004 ident: 10.1016/j.vaccine.2007.05.021_bib15 article-title: Meningococcal vaccines – year: 1999 ident: 10.1016/j.vaccine.2007.05.021_bib25 – volume: 5 start-page: 504 issue: 6 year: 2005 ident: 10.1016/j.vaccine.2007.05.021_bib40 article-title: Tackling the heterogeneity of CVID publication-title: Curr Opin Allergy Clin Immunol doi: 10.1097/01.all.0000191888.97397.b3 – volume: 117 start-page: 883 issue: 4 year: 2006 ident: 10.1016/j.vaccine.2007.05.021_bib7 article-title: Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2005.12.1347 – volume: 117 start-page: S435 issue: 2 Suppl. Mini-Primer year: 2006 ident: 10.1016/j.vaccine.2007.05.021_bib6 article-title: Update on primary immunodeficiency diseases publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2005.09.051 – volume: 12 start-page: 346 issue: 3 year: 2000 ident: 10.1016/j.vaccine.2007.05.021_bib21 article-title: Development and function of B-1 cells publication-title: Curr Opin Immunol doi: 10.1016/S0952-7915(00)00098-4 – volume: 15 start-page: 177 issue: 3 year: 2005 ident: 10.1016/j.vaccine.2007.05.021_bib23 article-title: Distribution of primary immunodeficiency disorders diagnosed in the Children's Medical Center in Iran publication-title: J Investig Allergol Clin Immunol – start-page: 289 year: 2004 ident: 10.1016/j.vaccine.2007.05.021_bib3 article-title: Immunologic disorders: general considerations – volume: 33 start-page: 81 issue: 1 year: 2004 ident: 10.1016/j.vaccine.2007.05.021_bib27 article-title: X-linked agammaglobulinemia: a survey of 33 Iranian patients publication-title: Immunol Invest doi: 10.1081/IMM-120027687 – volume: 349 start-page: 2353 year: 2003 ident: 10.1016/j.vaccine.2007.05.021_bib13 article-title: The meningococcal vaccine—public policy and individual choices publication-title: N Engl J Med doi: 10.1056/NEJMsb035678 – volume: 39 start-page: 651 year: 1992 ident: 10.1016/j.vaccine.2007.05.021_bib18 article-title: Recurrent meningitis in children publication-title: Pediatr Neurol – volume: 22 start-page: 375 issue: 6 year: 2002 ident: 10.1016/j.vaccine.2007.05.021_bib2 article-title: Primary immunodeficiency in Iran: first report of the national registry of PID in children and adults publication-title: J Clin Immunol doi: 10.1023/A:1020660416865 – volume: 92 start-page: 34 issue: 1 year: 1999 ident: 10.1016/j.vaccine.2007.05.021_bib9 article-title: Common variable immunodeficiency: clinical and immunological features of 248 patients publication-title: Clin Immunol doi: 10.1006/clim.1999.4725 – volume: 22 start-page: 1047 issue: 8 year: 2004 ident: 10.1016/j.vaccine.2007.05.021_bib38 article-title: Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines publication-title: Vaccine doi: 10.1016/j.vaccine.2003.08.040 – volume: 141 start-page: 408 issue: 4 year: 2006 ident: 10.1016/j.vaccine.2007.05.021_bib24 article-title: Clinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia publication-title: Int Arch Allergy Immunol doi: 10.1159/000095469 – volume: 10 start-page: 691 issue: 10 year: 1992 ident: 10.1016/j.vaccine.2007.05.021_bib31 article-title: Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C publication-title: Vaccine doi: 10.1016/0264-410X(92)90091-W – volume: 9 start-page: 722 year: 1952 ident: 10.1016/j.vaccine.2007.05.021_bib5 article-title: Agammaglobulinemia publication-title: Pediatrics doi: 10.1542/peds.9.6.722 – volume: 23 start-page: 2222 issue: 17–18 year: 2005 ident: 10.1016/j.vaccine.2007.05.021_bib32 article-title: Meningococcal surrogates of protection–serum bactericidal antibody activity publication-title: Vaccine doi: 10.1016/j.vaccine.2005.01.051 – volume: 19 start-page: 1327 issue: 11–12 year: 2001 ident: 10.1016/j.vaccine.2007.05.021_bib29 article-title: Development of natural immunity to Neisseria meningitides publication-title: Vaccine doi: 10.1016/S0264-410X(00)00333-9 – volume: 24 start-page: 4692 issue: 22 year: 2006 ident: 10.1016/j.vaccine.2007.05.021_bib14 article-title: A review of vaccine research and development: meningococcal disease publication-title: Vaccine doi: 10.1016/j.vaccine.2006.03.034 – volume: 115 start-page: 412 issue: 2 year: 2005 ident: 10.1016/j.vaccine.2007.05.021_bib43 article-title: The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2004.10.048 – volume: 12 start-page: 825 issue: 7 year: 2005 ident: 10.1016/j.vaccine.2007.05.021_bib16 article-title: Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency publication-title: Clin Diagn Lab Immunol doi: 10.1128/CDLI.12.7.825-832.2005 – volume: 279 start-page: 435 issue: 6 year: 1998 ident: 10.1016/j.vaccine.2007.05.021_bib20 article-title: Efficacy of meningococcal vaccine and barriers to vaccination publication-title: JAMA doi: 10.1001/jama.279.6.435 – volume: 54 start-page: 1 issue: RR-7 year: 2005 ident: 10.1016/j.vaccine.2007.05.021_bib12 article-title: Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP) publication-title: MMWR Recomm Rep – volume: 129 start-page: 1307 issue: 6 year: 1969 ident: 10.1016/j.vaccine.2007.05.021_bib36 article-title: Human immunity to the meningococcus. I: The role of humoral antibodies publication-title: J Exp Med doi: 10.1084/jem.129.6.1307 – volume: 86 start-page: 31 issue: 1 year: 1993 ident: 10.1016/j.vaccine.2007.05.021_bib8 article-title: Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications publication-title: Q J Med – ident: 10.1016/j.vaccine.2007.05.021_bib34 – volume: 72 start-page: 2049 issue: 10 year: 2005 ident: 10.1016/j.vaccine.2007.05.021_bib10 article-title: Prevention of meningococcal disease publication-title: Am Fam Physician – volume: 130 start-page: 2882 issue: 6 year: 1983 ident: 10.1016/j.vaccine.2007.05.021_bib37 article-title: IgA blocks IgM and IgG-initiated immune lysis by separate molecular mechanisms publication-title: J Immunol doi: 10.4049/jimmunol.130.6.2882 – volume: 10 start-page: 780 issue: 5 year: 2003 ident: 10.1016/j.vaccine.2007.05.021_bib39 article-title: Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England publication-title: Clin Diagn Lab Immunol doi: 10.1128/CDLI.10.5.780-786.2003 – volume: 57 start-page: 68 year: 1986 ident: 10.1016/j.vaccine.2007.05.021_bib19 article-title: Immunoglobulin deficiencies and meningococcal disease publication-title: Ann Allergy – volume: 4 start-page: 156 issue: 2 year: 1997 ident: 10.1016/j.vaccine.2007.05.021_bib26 article-title: Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group publication-title: Clin Diagn Lab Immunol doi: 10.1128/CDLI.4.2.156-167.1997 – volume: 8 start-page: 630 year: 1989 ident: 10.1016/j.vaccine.2007.05.021_bib28 article-title: Review of recurrent bacterial meningitis publication-title: Pediatr Infect Dis J doi: 10.1097/00006454-198909000-00013 – volume: 333 start-page: 431 issue: 7 year: 1995 ident: 10.1016/j.vaccine.2007.05.021_bib4 article-title: The primary immunodeficiencies publication-title: N Engl J Med doi: 10.1056/NEJM199508173330707 – volume: 60 start-page: 673 issue: 5 year: 1977 ident: 10.1016/j.vaccine.2007.05.021_bib35 article-title: Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines publication-title: Pediatrics doi: 10.1542/peds.60.5.673 – volume: 72 start-page: 1978 issue: 10 year: 2005 ident: 10.1016/j.vaccine.2007.05.021_bib11 article-title: Time of hope for the eventual elimination of meningococcal strains A, C, Y, and W-135 in the United States publication-title: Am Fam Physician – volume: 41 start-page: 1152 issue: 11 year: 2004 ident: 10.1016/j.vaccine.2007.05.021_bib17 article-title: Recurrent meningitis in association with common variable immune deficiency publication-title: Indian Pediatr – volume: 120 start-page: 225 issue: 2 year: 2000 ident: 10.1016/j.vaccine.2007.05.021_bib41 article-title: Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID) publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.2000.01131.x – volume: 115 start-page: 1220 issue: 5 year: 2005 ident: 10.1016/j.vaccine.2007.05.021_bib33 article-title: Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States publication-title: Pediatrics doi: 10.1542/peds.2004-2514 |
SSID | ssj0005319 |
Score | 2.019746 |
Snippet | Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by various... Abstract Primary antibody deficiencies are characterized by decreased serum levels of immunoglobulin isotypes and increased susceptibility to infection by... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 5308 |
SubjectTerms | Adolescent Age Allergy and Immunology Antibodies, Bacterial - blood Antibody response Applied microbiology Bacteria Bacteriology Biological and medical sciences Child Child, Preschool Female Fundamental and applied biological sciences. Psychology Heat Humans Immunologic Deficiency Syndromes - complications Kinases Male Meningitis Meningococcal disease Meningococcal Vaccines - immunology Microbial Viability Microbiology Microorganisms Miscellaneous Mortality Neisseria meningitidis Neisseria meningitidis, Serogroup C - immunology Patients Polysaccharide vaccine Primary antibody deficiencies Serum bactericidal antibody assay Streptococcus infections Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) |
SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELdgCISEEBQGgTH8gPa0dHbsfPgJoYlpQhqaxIb6ZiX2Req0JWVpkfo38E9zdpxGSJTx3Fyuzp3PP98nIR8Y8MqUVsU15yaWVmaxsqyKucitlIKpInXVyGdfs9NL-WWWzoLDrQtplYNN9Ibatsb5yI9c-Ax3BOL9j4sfsZsa5aKrYYTGffLAty5Dfc5n-ZjiIfxgD7xmyFhyNhsreI6upj9L40LXoYthOmUJ33Y2PVmUHX6xuh91sR2L-jPp5Bl5GsAk_dRL_zm5B82EPOzHS64n5NFZCJxPyMF536J6fUgvxoqr7pAe0POxeTXSTL67_BhfpEsH8hfkF5qU1Q2t-tbOZm6RK4pkXrV2TW_7NFugy5aiQre-UIQe00V7ve5w-fj-uQV6A84F06IBxkXS_rt4taDzhg415dT5hemib4ExsrDgGl2AGyTcvSSXJ58vjk_jMMYhNgjOlnGmAHGeKpQVdVom3FR4RWECchCgQBVJXSmEhVYAeO8KB1MIm4ILeFqW12KX7DRtA68JrQ2YrITCMFnLUsmyKEtem1rlruNEIiMiBwFqE3qcu1Eb13pIZrvSQe5u_mauWapR7hGZbsjCCu8iyAbt0EMFK9pcjcfQXYT53wihC5aj01x3iWb6G_NIlc3QJLO0KFREig1lAEc96Pkfpvt_KPC4xgKPGJbgu_cGjdbjH9lsuIi83_yMxsdFlMoG2lWHTETCheOw7YncQVq8YkTkVb9TRuZ56tCrfPNv5m_J48GdnrA9srO8XcE7xIHLat9v9t_TXV99 priority: 102 providerName: ProQuest |
Title | Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X07005889 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X07005889 https://dx.doi.org/10.1016/j.vaccine.2007.05.021 https://www.ncbi.nlm.nih.gov/pubmed/17574314 https://www.proquest.com/docview/1559088619 https://www.proquest.com/docview/20321321 https://www.proquest.com/docview/70663774 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1db9Mw0JqGQEgIQfkqjOEHtKeldWKnjh9HtamAVlWwob5ZiX2RMm1NtbRIfeEP8Kc5J07DBNMQL0mU-HI5-3J3tu-DkPcMwsykVgV5GJpAWDEKlGVZEHJpheBMJbGLRj6djibn4tM8nu-QcRsL49wqvexvZHotrf2doe_N4bIohl9ZrcvZHJmWxUnigviEkI7XBz9-c_PgdXEP1zhwrbsonuHF4Htq3Pa1z2QYD1gU3qafHi3TCnstb8pd3G6P1nrp5Al57A1KetR881OyA4seud-UmNz0yINTv3neIwezJk315pCedVFX1SE9oLMugTXC9L45H5k6UJe24M_ITxQr6yuaNemdTWERKw5LkZV2Q68bV1ugq5IiU5d1sAgd02V5uamQfHx_YYFegVuGKVEII5G06ZeaNWixoG1cOXVrw3TZpMHoUFhwyS7AFROunpPzk-Oz8STwpRwCgwbaKhgpQFtPJcryPE6j0GQ4TWEcJHBQoJIozxSahpYD1CssIZiE2xjcpqdlMucvyO6iXMArQnMDZpRCYpjIRapEmqRpmJtcSZd1IhJ9ItoB1MbnOXflNi5169B2of24uxqcUrNY47j3yWAL5im8C2DUcoduo1hR7mpURXcByr8BQuWlR6VDXUWa6T84vE-SLeSNn-RfkO7fYOCOxgTVDIvw3XstR-vuQ3C-iWoIJ9l98m77GAWQ21VKF1CuK0TCo5A7DLe1kM6sxWlGn7xs_pQOuYydBSte_z9hb8jDdrk9Yntkd3W9hrdoJ66y_VoQ4FHOJR6TMV7fO_r4eTLF84fj6ezLL8p6bnM |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVDwkhCC8AqXdA_RUp2t7HXsPCEFp1dI2iqCtclvs3bGUqo1DnYDyG_gv_EZm_YiFRCiXnpPZyWYe--3OC-A1RzfRsZFO6rraEUb0HGl44rh-aITwuYwCW4183O_tn4pPw2C4Ar_qWhibVln7xMJRm0zbN_JtGz4jiyC8_27yzbFTo2x0tR6hUarFIc5_0JUtf3vwkeT7xvP2dk929p1qqoCjCStMnZ5Egh0yksZPg9hzdUKImfsYoo8SZeSliSSUYnzE4rLvoo58E6CNvxkepj6tewtWha1obcHqh93-4HOTVOIXo0ToYiMc4fJhUzO0fd79HmsbLK_6JgZd7rnLTsP7kzgnGaXlcI3l6Lc4BfcewoMKvrL3pb49ghUct-F2OdBy3oY7x1Wovg2bg7Ip9nyLnTQ1XvkW22SDpl020bTPbEZOURbMavLH8JOc2OySJWUzaT0yxJWUYJRkZs6uysReZNOMkQllRWkK22GT7GKe0_Zp_ZFBdon20Scjl0-bZOX_UigiG41ZXcXO7Es0m5RNNxoWBm1rDbSji_MncHojIn4KrXE2xufAUo26F2OkuUhFLEUcxbGb6lSGtseFJzogagEqXXVVt8M9LlSdPneuKrnbiZ-h4oEiuXeguyCrdngdQa_WDlXXzJKXV3TwXUcY_o0Q88pX5cpVuae4-sILbMyHdAjwIIpkB6IFZQXHSpj1P0zX_1DgZo8RHWrco7XXao1WzQ9ZmHgHNhYfk7uzMax4jNksJya-5_qWw7JvhBZE06WmA89KS2mYh4HFy-LFv5lvwN39k-MjdXTQP3wJ9-rHfI-vQWt6NcNXhEKnyXpl-gy-3rS3-Q0kPZyo |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEBMSQlBuhbH5Afa0tE7s1PEDQmij2hibKrGhvnmJfSJ12pKytKD-Bv4Rv47jXBohUcbLntvjU_dc_NnnRsgbBn5iYqu81PeNJ6wYeMqyxPO5tEJwpqLQVSMfnwwOzsSncTheI7-aWhiXVtn4xNJR29y4N_K-C5-hRSDe76d1WsRof_h--s1zE6RcpLUZp1GpyBEsfuD1rXh3uI-yfhsEw4-newdePWHAM4gbZt5AAUIQFSnL0zAOfJMgemYcJHBQoKIgTRQiFssByou_DybiNgQXi7NMphzXvUPuSo6oCm1JjmWbXsLLoSJ4xRGe8Nm4rR7qX_S-x8aFzesOimGPBf6qc_HBNC5QWmk1ZmM1Di7Pw-Ej8rAGsvRDpXmPyRpkHXKvGm256JCN4zpo3yE7o6o99mKXnrbVXsUu3aGjtnE20nS-utycskCYNuRPyE90Z_MrmlRtpc3EIldUh0mS2wW9rlJ8gc5yisaUl0UqdI9O88tFgdvH9ScW6BW4558cnT9uklb_S6mSdJLRpp6dujdpOq3ab7QsLLgmG-CGGBdPydmtCPgZWc_yDF4Qmhowgxgiw0QqYiXiKI791KRKum4XgegS0QhQm7q_uhvzcambRLoLXcvdzf6UmoUa5d4lvSVZvcObCAaNduimehb9vcYj8CZC-TdCKGqvVWhfF4Fm-gsrUTIb43HAwihSXRItKWtgVgGu_2G69YcCt3uM8HhjAa692Wi0bn_I0ti7ZHv5MTo-F82KM8jnBTLhgc8dh1XfkA5O4_WmS55XltIyl6FDzuLlv5lvkw30Mfrz4cnRK3K_edUP2CZZn13P4TXC0VmyVdo9Jee37Wh-A1sMn28 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+bactericidal+antibody+response+to+serogroup+C+polysaccharide+meningococcal+vaccination+in+children+with+primary+antibody+deficiencies&rft.jtitle=Vaccine&rft.au=Rezaei%2C+Nima&rft.au=Aghamohammadi%2C+Asghar&rft.au=Siadat%2C+Seyed+Davar&rft.au=Nejati%2C+Mehdi&rft.date=2007-07-20&rft.issn=0264-410X&rft.volume=25&rft.issue=29&rft.spage=5308&rft.epage=5314&rft_id=info:doi/10.1016%2Fj.vaccine.2007.05.021&rft.externalDBID=NO_FULL_TEXT |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X07X04250%2Fcov150h.gif |